



Curriculum Vitae

Personal information **Jan Vosatka**

Work experience

1. Employer: Pharmacy chain Dr. Max
 - Start date: 112021
 - End date:
 - Position: Community pharmacist
 - Activities: Pharmaceutical care (dispensation of OTC and Rx drugs)
 - Country: Czechia
2. Employer: Pharmacy Fenix
 - Start date: 052016
 - End date: 102021
 - Position: Community pharmacist
 - Activities: Pharmaceutical care (dispensation of OTC and Rx drugs)
 - Country: Czechia
3. Employer: State Institute For Drug Control
 - Start date: 102019
 - End date:
 - Position: Pharmacovigilance assessor
 - Activities: Performance of pharmacovigilance assessment
 - Country: Czechia

Education and training

1. Subject: Faculty of Pharmacy in Hradec Kralove, Charles University
 - Start date: 102010
 - End date: 092015
 - Qualification: Master of Pharmacy
 - Organisation:
 - Country: Czechia
2. Subject: Faculty of Pharmacy in Hradec Kralove, Charles University
 - Start date: 102015
 - End date: 092024 (no defense)
 - Qualification: PhD student (no defense)
 - Organisation: Clinical pharmacy, pharmacoepidemiology, pharmaceutical care
 - Country: Czechia

Additional information

Publications

Maly J, Dosedel M, Vosatka J, Mala_Ladova K, Kubena AA, Brabcova I, et al. Pharmacotherapy as major risk factor of falls _ analysis of 12 months experience in hospitals in South Bohemia. J Appl Biomed. 2019;17(1):60. doi: 10.32725/jab.2019.001. Maly, J, Dosedel, M, Kubena, AA, et al. Analysis of the fall - related risk of pharmacotherapy in Czech hospitals: A case control study. J Eval Clin Pract. 2020; 26: 973- 982. <https://doi.org/10.1111/jep.13270>

Doseděl M, Malý J, Vosátka J, et al. Clinical pharmacist involvement in fall management in a polymorbid geriatric patient with a history of recurrent falls. Zapojení klinického farmaceuta do managementu pádů u polymorbidního geriatrického pacienta s opakovanými pády v anamnéze. Ceska Slov Farm. 2018;67(5_6):205_211.

Projects

Memberships

Other Relevant Information

PRAC Co_Rapporteur team Referral under Article 31 of Directive 2001/83/EC - reevaluation of benefit_risk balance of amfepramone_containing medicinal products - EMA/844036/2022

PRAC Rapporteur team Referral under Article 31 of Directive 2001/83/EC - Dutasteride; dutasteride, tamsulosin; finasteride; finasteride, tadalafil - EMEA/H/A-31/1539